Erythematotelangiectatic Rosacea Clinical Trial
Official title:
Combination Therapy for the Treatment of Erythematotelangiectatic Rosacea
The purpose of this study is to determine the efficacy of calcium dobesilate in combination with pulsed dye laser for the treatment of rosacea.
Rosacea is a common cutaneous disorder characterized by facial erythema, papules and pustules
and telangiectasias. The clinical manifestations of this disorder are distributed along the
convexities of the face such as the cheeks, chin, nose and central aspects of the forehead.
The flushing and telangiectasias associated with erythematotelangietatic rosacea (ETR) are
notoriously difficult to treat with standard medications. Patients with ETR have a lower
threshold for irritation from topically applied drugs and these substances may even
exacerbate their symptoms.
Pulsed dye laser (PDL) is widely considered as the treatment of choice for vascular
malformations including telangiectasias, port wine stains and hemangiomas. Several studies
have shown successful treatment of rosacea-associated telangiectasia and erythema with pulsed
dye laser. Moreover, calcium dobesilate (2,5-dihydroxybenzene sulfonate) is a drug that
inhibits vascular smooth muscle cell growth and inhibits cellular proliferation. As a
synthetic inhibitor of fibroblast growth factor (FGF), calcium dobesilate targets angiogenic
growth factors which lead to uncontrolled blood vessel growth. In light of the fact that
angiogenesis has been implicated in erythematotelangietatic rosacea, calcium dobesilate will
be useful in the treatment of this subtype of rosacea.
Thus, combination treatment with PDL and calcium dobsilate will act in a synergistic manner
to reduce the erythema, flushing and telangectasia associated with erythematotelangietatic
rosacea.
If the subject meets the inclusion criteria and informed consent is obtained, the subject
will receive 2.5% calcium dobesilate get to apply to half of the face (randomized). The
subject will also receive pulsed dye laser treatments to the whole face at two week intervals
for a maximum of 3 treatments. The primary endpoint of this study will be the severity of
rosacea at the end of the 20 week study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03708263 -
Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea
|
N/A | |
Completed |
NCT02268474 -
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
|
N/A | |
Completed |
NCT00989014 -
Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea
|
Phase 2 | |
Completed |
NCT01756027 -
Feasibility Study: Ulthera System for the Treatment of Rosacea
|
N/A | |
Completed |
NCT06331533 -
Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea
|
Phase 4 | |
Completed |
NCT02144181 -
Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea
|
N/A | |
Recruiting |
NCT05360251 -
Pulsed Dye Laser and Intense Pulsed Light Configured With Different Wavelength Bands in Improving Erythematotelangiectatic Rosacea
|
N/A | |
Completed |
NCT01045551 -
Open Label Pilot Study of Apremilast in Treatment of Rosacea
|
Phase 2 | |
Completed |
NCT04153188 -
Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
|
Phase 4 | |
Completed |
NCT02393937 -
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
|
Phase 3 | |
Completed |
NCT02052999 -
Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients
|
Phase 2 |